Abstract Library

#2291 Somatostatin Analogs and mTOR Inhibitors as Radioprotectors or Radiosensitizers in Neuroendocrine Tumor Cells

Introduction: Neuroendocrine tumors (NETs) express somatostatin receptors that are currently utilized for diagnostic and therapeutic approaches. For peptide receptor radionuclide therapy (PRRT), somatostatin analogs are coupled to radionuclides like 90Y or 177Lu, which after injection are bound and taken up specifically by NETs. One hypothesis potentially explaining the discrepancies between expected result and observed outcome of PRRT might be that somatostatin analogs induce a G1 arrest in NET cells, thereby rendering them radioresistant.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Grötzinger C

Authors: Grötzinger C, Exner S, Prasad V, Erdmann S, Wiedenmann B,

Keywords: PRRT,

#1098 177Lu Dotatate vs Sequential 177Lu Dotatate and 90Y Dotatate: Treatment Outcomes for PRRT Patients at the Christie - A Clinical Audit

Introduction: The traditional treatment regime of somatostatin receptor positive NETs by molecular radiotherapy was based on single radionuclides (e.g. 90Y Dotatate or 177Lu Dotatate), delivered as multiple cycles to allow normal tissue recovery. However a newer practice of alternating tcycles of 177Lu and Y90 Dotatate was implemented at the Christie following introduction of this regime in some European centres. Subsequent follow up studies have indicated that longer overall survival and reduced loss of kidney function is found in patient cohorts treated with combined 177Lu and 90Y regimes to either 177Lu or 90Y alone.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Tipping J

Authors: Page E, Tipping J, Birch E, Hamilton D, Manoharan P,

Keywords: PRRT, Toxicity, Audit, RM Dose,

#610 Effectiveness of PRRT for NETs in Germany: An Analysis of 450 Patients

Introduction: Peptide receptor radionuclide therapy targets somatostatin receptors expressed on well-differentiated neuroendocrine neoplasms. Retrospective monocentric studies indicate that peptide receptor radionuclide therapy is an effective treatment for patients with neuroendocrine neoplasms.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: Hörsch D

Authors: Hörsch D, Ezziddin S, Haug A, Gratz K, Dunkelmann S,

Keywords: PRRT,

#450 Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors in Germany: First Results of a Multiinstitutional Cancer Registry

Introduction: Peptide receptor radionuclide therapy is an effective treatment option for patients with well-differentiated somatostatin receptor expressing neuroendocrine tumors. However, published data results mainly from retrospective monocentric studies.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Hörsch D, Ezziddin S, Haug A, Gratz K, Dunkelmann S,

Keywords: PRRT, Yttrium, Lutetium, SMS Receptor,

#252 Y90-DOTATATE in Gastroenteropancreatic neuroendocrine tumors (GEP-NETs): Survival Following Different Indications for Treatment

Introduction: Peptide Receptor Radionuclide Therapy (PRRT) is an increasingly used treatment for GEP -NETs but there is limited data on indications, efficacy and survival.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Khan M, El-Khouly F, Quigley A, Caplin M, Toumpanakis C,

Keywords: neuroendocrine tumor, radionuclides, survival, therapy,